Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Transcenta Cleared to Proceed in a US Phase III Trial of CLDN18.2 Antibody

publication date: Oct 4, 2023

Suzhou Transcenta was approved to start a US Phase III trial of Osemitamab, a CLDN18.2 antibody, in patients with metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma. The candidate will be administered as a first-line therapy in patients with HER2-negative, CLDN18.2 disease along with chemotherapy and/or Opdivo (nivolumab), a PD-1 drug. Transcenta says Osemitamab is a second-gen CLDN18.2 targeting antibody with improved binding affinity and enhanced cellular cytotoxicity. The US trial is part of a global Osemitamab trial being conducted by Transcenta, which has already been approved to begin the China arm. More details....

Stock Symbol: (HK: 06628)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital